Biocon and Genentech have reached a global patent settlement and licence agreement establishing planned launch windows for Pebrilzo, Biocon's pertuzumab biosimilar to Perjeta.

Biocon has secured a 10-year pertuzumab supply partnership in Brazil under the country's Productive Development Partnership programme.

The supplemental approval introduces a new self-injection option for patients receiving Yesintek across its approved autoimmune indications without changing the medicine's existing therapeutic uses.